Results 251 to 260 of about 1,464,129 (347)

Precision Oncology Medicine: The Clinical Relevance of Patient‐Specific Biomarkers Used to Optimize Cancer Treatment

, 2016
Keith T. Schmidt, Cindy H. Chau, Douglas K. Price, William D. Figg   +3 more
openalex   +1 more source

Cell surface interactome analysis identifies TSPAN4 as a negative regulator of PD‐L1 in melanoma

Molecular Oncology, EarlyView.
Using cell surface proximity biotinylation, we identified tetraspanin TSPAN4 within the PD‐L1 interactome of melanoma cells. TSPAN4 negatively regulates PD‐L1 expression and lateral mobility by limiting its interaction with CMTM6 and promoting PD‐L1 degradation.
Guus A. Franken, Andrea Abel Gutierrez, Imke van Rossum, Cornelia G. Spruijt, Michiel Vermeulen, Guido van Mierlo, Blanca Scheijen, Annemiek B. van Spriel   +7 more
wiley   +1 more source

Supplementum 283: Abstracts of the Swiss Oncology & Hematology Congress (SOHC)

Swiss Medical Weekly
Swiss Society of Medical Oncology, Swiss Society of Hematology, Swiss Group for Clinical Cancer Research   +2 more
doaj   +1 more source

When molecular biology transforms clinical oncology: the EGFR journey in colorectal cancer. [PDF]

Mol Oncol
Vitiello PP, Saoudi González N, Bardelli A.   +2 more
europepmc   +1 more source

PARP inhibition and pharmacological ascorbate demonstrate synergy in castration‐resistant prostate cancer

Molecular Oncology, EarlyView.
Pharmacologic ascorbate (vitamin C) increases ROS, disrupts cellular metabolism, and induces DNA damage in CRPC cells. These effects sensitize tumors to PARP inhibition, producing synergistic growth suppression with olaparib in vitro and significantly delayed tumor progression in vivo. Pyruvate rescue confirms ROS‐dependent activity.
Nicolas Gordon, Peter T. Gallagher, Orly I. Richter, Neermala Poudel Neupane, Amy C. Mandigo, Jennifer J. McCann, Emanuela Dylgjeri, Irina Vasilevskaya, Christopher McNair, Channing J. Paller, Wm. Kevin Kelly, Karen E. Knudsen, Matthew J. Schiewer, Ayesha A. Shafi   +13 more
wiley   +1 more source

Stereotactic MR-guided online adaptive radiation therapy (SMART) for ultracentral thorax malignancies: Results of a phase 1 trial [PDF]

, 2018
Bradley, Jeffrey D, Contreras, Jessika A, Curcuru, Austen, DeWees, Todd A, Green, Olga L, Henke, Lauren E, Kashani, Rojano, Michalski, Jeff, Mutic, Sasa, Olsen, Jeffrey R, Parikh, Parag J, Roach, Michael C, Robinson, Clifford G   +12 more
core   +1 more source

Competing risks data in clinical oncology. [PDF]

Front Oncol
Kim HT.
europepmc   +1 more source

Review: Accelerating eSource scale-up in oncology clinical trials: The i~HD Task Force initiative — R1/PR8

Christophe Maes, Dipak Kalra, Tracy Acito, Nadir Ammour, Paul Basset, Sarah Burge, Peter Castleyn, Ross Caldow, Camille Couvert, Amy Cramer, Chris Harrison, Joeri Holtzem, Pavitra Mariappan, Paul Jacobs, Lars Fransson, Veronique Berthou, Laurice Jackson, Nancy Wetzel, Christopher Thompson, Sharon Klein, Robert Green, Fakhry Kaoukdji, Michael Ward, Felix Nensa, Joe Lengfellner, Anna Patruno, Dawn Snow, Isabel Virchow, Angela Fritsche, Pascal Coorevits, Mats Sundgren   +30 more
openalex   +1 more source

LDAcoop: Integrating non‐linear population dynamics into the analysis of clonogenic growth in vitro

Molecular Oncology, EarlyView.
Limiting dilution assays (LDAs) quantify clonogenic growth by seeding serial dilutions of cells and scoring wells for colony formation. The fraction of negative wells is plotted against cells seeded and analyzed using the non‐linear modeling of LDAcoop.
Nikko Brix, Daniel Samaga, Katharina Gehr, Benedek Dankó, Mohamed Schumann, Guido Drexler, Ahmed Alnatsha, Georg Beyer, Ujjwal Mahajan, Martin Selmansberger, Julia Mayerle, Claus Belka, Horst Zitzelsberger, Kirsten Lauber   +13 more
wiley   +1 more source

Study protocol of a randomized controlled phase II trial comparing nivolumab, ipilimumab plus radiotherapy versus nivolumab plus ipilimumab for advanced or recurrent esophageal cancer: Japan Clinical Oncology Group study JCOG2311 (ART NOUVEAU). [PDF]

BMC Cancer
Sakanaka K, Sasaki K, Tsushima T, Machida R, Hamai Y, Watanabe A, Kawabata K, Matsuda S, Kato K, Fukuda H, Takeuchi H, Japan Esophageal Oncology Group of the Japan Clinical Oncology Group.   +11 more
europepmc   +1 more source